Rain Therapeutics Stock Forecast, Price & News

+0.23 (+1.56 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume35,861 shs
Average Volume138,557 shs
Market Capitalization$397.27 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RAIN News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Rain Therapeutics

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.30 out of 5 stars

Medical Sector

245th out of 1,351 stocks

Pharmaceutical Preparations Industry

117th out of 664 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Rain Therapeutics (NASDAQ:RAIN) Frequently Asked Questions

Is Rain Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rain Therapeutics stock.
View analyst ratings for Rain Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Rain Therapeutics?

Wall Street analysts have given Rain Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rain Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rain Therapeutics' next earnings date?

Rain Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Rain Therapeutics

How were Rain Therapeutics' earnings last quarter?

Rain Therapeutics Inc. (NASDAQ:RAIN) posted its earnings results on Tuesday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.11.
View Rain Therapeutics' earnings history

What price target have analysts set for RAIN?

4 equities research analysts have issued 1 year price targets for Rain Therapeutics' stock. Their forecasts range from $22.00 to $26.00. On average, they expect Rain Therapeutics' share price to reach $24.33 in the next year. This suggests a possible upside of 62.1% from the stock's current price.
View analysts' price targets for Rain Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rain Therapeutics' key executives?

Rain Therapeutics' management team includes the following people:
  • Mr. Avanish Vellanki M.B.A., Co-Founder, CEO & Chairman (Age 46)
  • Dr. Robert C. Doebele M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer (Age 50)
  • Mr. Nelson D. Cabatuan, Sr. VP of Fin. & Admin. (Age 43)
  • Ms. Theresa O'Connell M.S., Director of Corp. Devel. & Operations
  • Ms. Jamie S. Blose J.D., M.B.A., Pharm.D., VP & Head of Legal Affairs
  • Ms. Vijaya Tirunagaru Ph.D., Sr. VP & Head of Research
  • Mr. Lucio Tozzi, Sr. VP of Clinical Operations (Age 57)
  • Dr. Richard P. Bryce, Exec. VP & Chief Medical Officer (Age 64)
  • Kolbot By Ph.D., Sr. VP of Technical Operations

When did Rain Therapeutics IPO?

(RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO.

What is Rain Therapeutics' stock symbol?

Rain Therapeutics trades on the NASDAQ under the ticker symbol "RAIN."

When does Rain Therapeutics' lock-up period expire?

Rain Therapeutics' lock-up period expires on Wednesday, October 20th. Rain Therapeutics had issued 7,352,941 shares in its initial public offering on April 23rd. The total size of the offering was $124,999,997 based on an initial share price of $17.00. After the end of Rain Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Rain Therapeutics' major shareholders?

Rain Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.58%), Perceptive Advisors LLC (9.58%), BVF Inc. IL (7.35%), Samsara BioCapital LLC (6.18%), Boxer Capital LLC (4.44%) and FMR LLC (3.02%). Company insiders that own Rain Therapeutics stock include Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends for Rain Therapeutics

Which major investors are buying Rain Therapeutics stock?

RAIN stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, BVF Inc. IL, Samsara BioCapital LLC, Boxer Capital LLC, FMR LLC, Logos Global Management LP, and Vanguard Group Inc.. Company insiders that have bought Rain Therapeutics stock in the last two years include Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Perceptive Advisors Llc, and Value Fund L P Biotechnology.
View insider buying and selling activity for Rain Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Rain Therapeutics?

Shares of RAIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Therapeutics' stock price today?

One share of RAIN stock can currently be purchased for approximately $15.01.

How much money does Rain Therapeutics make?

Rain Therapeutics has a market capitalization of $397.27 million.

What is Rain Therapeutics' official website?

The official website for Rain Therapeutics is

How can I contact Rain Therapeutics?

The company can be reached via phone at 510-953-5559.

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.